1

# 1 Stratifying IVF population endometria using a prognosis

# 2 gradient independent of endometrial timing

- 3
- 4 Josefa Maria SANCHEZ-REYES, Ph.D.<sup>a,b,π</sup>
- 5 Antonio PARRAGA-LEO, M.Sc.<sup>a,b,π</sup>
- 6 Patricia SEBASTIAN-LEON, Ph.D.<sup>a</sup>
- 7 Maria del Carmen VIDAL, M.D.<sup>c</sup>
- 8 Diana MARTI-GARCIA, M.Sc.<sup>a,b</sup>
- 9 Katharina SPATH, Ph.D.<sup>d</sup>
- 10 Immaculada SANCHEZ-RIBAS, M.D., Ph.D.<sup>e</sup>
- 11 Francisco José SANZ, Ph.D.<sup>a</sup>
- 12 Nuria PELLICER, M.D., Ph.D.<sup>c</sup>
- 13 Jose REMOHI, M.D., Ph.D.<sup>b,c</sup>
- 14 Dagan WELLS, Ph.D.<sup>d,f</sup>
- 15 Antonio PELLICER, M.D., Ph.D.<sup>b,g</sup>
- <sup>16</sup> Patricia DIAZ-GIMENO, Ph.D.<sup>a\*</sup>
- 17
- <sup>a</sup> IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación
- 19 Sanitaria La Fe, Av. Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026
- 20 Valencia, Spain.

2

- <sup>b</sup> Department of Pediatrics, Obstetrics & Gynecology, University of Valencia, Av.
- 22 Blasco Ibañez 15, 46010 Valencia, Spain.
- <sup>23</sup> <sup>c</sup> IVIRMA Global Research Alliance, IVIRMA IVI Valencia, Plaza de la Policia
- Local 3, 46015 Valencia, Spain.
- <sup>d</sup> JUNO Genetics, Winchester house, Edmund Halley Rd. Science Park, Oxford
- 26 OX4 4GE, United Kingdom.
- <sup>e</sup> IVIRMA Global Research Alliance, IVIRMA IVI Barcelona, Calle Mallorca 45,
- 28 08029 Barcelona, Spain.
- <sup>1</sup> <sup>f</sup> Nuffield Department of Women's & Reproductive Health, University of Oxford,
- 30 Level 3, Women's Centre John Radcliffe Hospital, Oxford OX3 9DU, United
- 31 Kingdom.
- <sup>32</sup> <sup>9</sup> IVIRMA Global Research Alliance, IVIRMA IVI Rome, Largo Ildebrando
- 33 Pizzetti 1, Piano Rialzato 00197 Rome, Italy.
- <sup>34</sup> <sup>T</sup> Josefa Maria SANCHEZ-REYES and Antonio PARRAGA-LEO are joint first
- 35 authors.
- 36
- 37 \*Corresponding author:

## 38 Patricia DIAZ-GIMENO

- IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación
   Sanitaria La Fe (IIS La Fe), Valencia, Spain.
- 41
- 42 Edificio Biopolo Instituto de Investigación Sanitaria la Fe
- 43 Avenida Fernando Abril Martorell, 106 Torre A, Planta 1ª, 46026 Valencia
- 44 Tel: +34 96 390 33 05
- 45 email: patricia.diaz@ivirma.com / patricia\_diaz@iislafe.es

3

#### 46

## 47 Conflict of interest

- 48 The authors report no conflicts of interest.
- 49

## 50 Funding

This study was supported by the IVI Foundation (1706-FIVI-048-PD); Instituto 51 de Salud Carlos III (ISCIII) and co-funded by the European Regional 52 Development Fund "A way to make Europe" (PI19/00537 [P.D.-G.]). Patricia 53 54 Diaz-Gimeno is supported by Instituto de Salud Carlos III (ISCIII) through the Miguel Servet program (CP20/00118) co-funded by the European Union. 55 Patricia Sebastian-Leon is funded by Instituto de Salud Carlos III (ISCIII) 56 through the Sara Borrell postdoctoral program (CD21/00132 [P.S.-L.]) co-57 financed by the European Union. Josefa Maria Sanchez-Reyes was supported 58 59 by a predoctoral fellowship program of the Generalitat Valenciana (ACIF/2018/072 [J.M.S.-R.], BEFPI/2020/028 [J.M.S.-R.]). Antonio Parraga-Leo 60 61 (FPU18/01777 [A.P.-L.]) and Diana Marti-Garcia (FPU19/03247 [D.M.-G.]) were supported by predoctoral fellowship programs of the Spanish Ministry of 62 Science, Innovation and Universities. 63

64

## 65 **Paper presentation information**

Some of the findings reported in this scientific article were presented at the 78<sup>th</sup>
American Society for Reproductive Medicine Scientific Congress & Expo
(ASRM) held in Anaheim, California, USA, October 22-26, 2022.

#### 69 **ABSTRACT**

**Background:** Independent of endometrial timing, there are molecular causes of implantation failure that disrupt the endometrial transcriptome in the midsecretory phase. However, the molecular mechanisms disrupting the window of implantation (WOI) remain poorly understood. The molecular heterogeneity of this endometrial disruption must be characterized to develop personalized and more accurate diagnostic tools for preventive medicine, particularly for patients with a high risk of endometrial failure.

Objective(s): This study aimed to stratify and characterize the disrupted WOI
patterns using endometrial timing-corrected whole gene expression and artificial
intelligence (AI) models in *in vitro* fertilization (IVF) patients undergoing
hormone replacement therapy (HRT).

Study design: This multicenter prospective study was conducted between 81 January 2019 and August 2022. Endometrial biopsies were collected during the 82 83 mid-secretory phase for whole endometrial transcriptome analysis using RNA-Sequencing. To identify disruptions in the WOI, the transcriptomic variation due 84 to cyclic endometrial tissue changes was removed. Out of 195 biopsies 85 86 sequenced, 131 were derived from patients that met the clinical criteria to be classified as having a poor prognosis (≥3 implantation failures, n=32) or good 87 prognosis (<3 implantation failures, n=99). The 131 patients were randomly 88 89 allocated to training (n=105) and test (n=26) sets for biomarker signature discovery and assessment of predictive performance, respectively. The 90 91 reproductive outcomes of the single embryo transfer immediately after biopsy 92 collection were analyzed. Differential gene expression and functional analyses 93 were performed to characterize molecular profiles. Finally, a quantitative

5

94 polymerase chain reaction (qPCR) assay was used to corroborate the
95 differential expression of six potential biomarkers.

Results: With the dichotomous clinical classification of poor or good 96 97 reproductive prognosis, there was no transcriptomic distinction between 98 patients with a history of implantation failures during HRT endometrial 99 preparation. Alternatively, using an AI model to stratify IVF patients based on the probability of endometrial disruption revealed molecular and clinical 100 differences between profiles. Patients were stratified into four reproductive 101 prognosis-related profiles, p1 (n=24), p2 (n=14), c2 (n=32) and c1 (n=61). The 102 103 highest pregnancy rate (PR) was associated with c1 (91%) and the highest 104 ongoing pregnancy rate (OPR) was associated with c2 (78%), linking these 105 profiles to good reproductive prognoses. On the other hand, p1 had the highest 106 biochemical miscarriage rate (BMR; 43%) while p2 had the highest clinical miscarriage rate (CMR; 43%). Notably, both p1 and p2 were related to lower PR 107 and OPR, supporting that these profiles were associated with poor prognoses. 108 Regarding the functional characterization in the poor prognosis profiles that 109 110 were linked to miscarriages, p1 was associated with an excessive immune 111 response against the embryo during early pregnancy stages, while p2 was 112 initially immune-tolerant but rejected the fetus in later stages due to the lack of metabolic response. 113

**Conclusion(s):** This new AI-based prognostic stratification of IVF patients is promising for the clinical management of endometrial-factor infertility in precision medicine.

6

Keywords: gene expression signature, endometrial disruption, endometrial
function, artificial intelligence, transcriptomic stratification, infertility, precision
medicine.

120

# INTRODUCTION

121 Maternal endometrial status is a key factor in successful embryo implantation and development in assisted reproductive technologies (ARTs).<sup>1</sup> Cyclical 122 physiological changes occur in the endometrium during the luteal phase to 123 facilitate embryo implantation. Maximum uterine receptivity occurs during the 124 window of implantation (WOI) in the mid-secretory phase.<sup>2-5</sup> To ensure 125 126 endometrial factor success, the endometrium must synchronize with the embryo during the WOI,<sup>6-9</sup> and endometrial function must be undisrupted.<sup>10-12</sup> After 127 128 successful embryo implantation, the endometrium must support placentation 129 and provide an optimal equilibrium of embryo-maternal interactions as well as adequate vascularization for fetal growth.<sup>13</sup> 130

Despite the development of ARTs, approximately 35% of transferred euploid 131 embryos do not implant in anatomically normal uteri at the first attempt.<sup>14</sup> 132 133 Patients experiencing successive implantation failures are clinically classified as having recurrent implantation failure (RIF), however, there is a lack of 134 consensus on the definition of RIF.<sup>14,15</sup> The heterogeneous etiology and clinical 135 symptoms of RIF do not provide sufficient criteria to stratify patients.<sup>10,16</sup> Indeed, 136 the molecular heterogeneity of RIF patients highlights opportunities to 137 characterize the molecular profiles that contribute to the interpatient variability, 138 139 discover new biomarkers and develop tailored treatments.

7

The combined use of transcriptomics and artificial intelligence (AI) algorithms has significantly advanced the understanding of endometrial-factor infertility.<sup>10–</sup> 142 <sup>12,17–19</sup> This work is laying the groundwork for new applications in precision medicine and ARTs, facilitating the characterization of reproductive diseases, patient diagnosis and prognosis. In this context, accurate patient stratification is necessary to match treatment to the right patient.<sup>20–22</sup>

146 Leveraging the use of AI algorithms, our group recently proposed a biomarker signature in luteal-phase endometrial biopsies that stratifies ART patients 147 undergoing hormone replacement therapy (HRT) into poor or good reproductive 148 prognosis, independent of endometrial timing.<sup>12</sup> In contrast to previous studies 149 performed in natural cycles,<sup>10</sup> this prospective study included clinical follow-up 150 151 to investigate if the prognostic transcriptome-based groups were related to 152 reproductive outcomes. Despite using a 404-gene panel, dichotomous patient classification into poor or good prognosis was limited by the molecular 153 complexity of implantation failure that requires the identification of more 154 subtypes.<sup>12</sup> 155

Hence, the current prospective study was designed to use the whole transcriptomic profile to reproduce and refine our previous classification in a new cohort of patients undergoing HRT. Our new prognostic stratification elucidates the molecular heterogeneity of the endometrial disruptions in the mid-secretory phase, independent of endometrial timing.

161

# MATERIALS AND METHODS

## 162 Ethics statement

8

This study was approved by the Ethics Committee of the Instituto Valenciano de
Infertilidad (Valencia, Spain; 1706-FIVI-048-PD). Written informed consent was
obtained from all participants.

#### 166 Participants and clinical follow-up

Participants (n=291) were recruited for a multicentric, prospective study 167 between January 2019 and August 2022 at five private fertility clinics in Spain. 168 169 Participants were scheduled for endometrial evaluation before embryo transfer 170 due to medical indications, and met the following inclusion criteria: 18–50 years old, with a body mass index (BMI) of 19-30 kg/m<sup>2</sup>, undergoing HRT prior to 171 172 single embryo transfer (SET) with a good-quality embryo (euploidy guaranteed 173 by preimplantation genetic testing or oocytes from donors <35 years old), and 174 presenting an endometrial thickness >6.5 mm with trilaminar structure in proliferative phase. Exclusion criteria were male-factor infertility (in cases with 175 176 autologous sperm) as the only treatment indication, untreated reproductive pathologies that may compromise endometrial function, severe pre-menopausal 177 symptoms, uncontrolled systemic or metabolic disorders, and co-administered 178 medication that can interfere with ARTs. 179

Baseline participant characteristics were obtained from internal medical records,
in accordance with data protection laws in Spain.

#### 182 Study design

183 IVF patients undergoing HRT were clinically classified according to their history 184 of implantation failures. Endometrial biopsies were collected during the mid-185 secretory phase for RNA-Sequencing (RNA-Seq) analysis. An AI probabilistic 186 model was developed based on the transcriptome independent of endometrial

9

timing, avoiding biases in transcriptomic variation due to cyclical changes in the
endometrium (Supplementary Material). The Al-determined probability of a
poor prognosis was used to stratify the population. Finally, the clinical outcomes
and molecular functions of the stratified profiles were studied (Figure 1).

## 191 Endometrial biopsy collection, sequencing and data processing

192 Endometrial biopsies were obtained from the uterine fundus, using a cannula 193 (Pipelle Cornier, CCD Laboratories, Paris, France) under sterile conditions, after 194 approximately 120 hours of progesterone treatment in the HRT cycles. Anonymized samples were stored in RNA-later® (Sigma-Aldrich, Madrid, Spain) 195 196 at -80°C. RNA was extracted using the miRNeasy Mini Kit following 197 manufacturer's instructions (Qiagen, Hilden, Germany). RNA quality was 198 assessed using the NanoDrop<sup>™</sup> One (AF-00342, ThermoFisher Scientific, Valencia, Spain) and 4200 TapeStation System<sup>®</sup> (Agilent, Valencia, Spain). 199 200 Only samples that met the following RNA quality criteria were included in the 201 study: 260/280 ratio ~2.0, 260/230 ratio=1.8-2.2, RNA integrity number (RIN) 202 ≥3 and RNA fragments with more than 200 nucleotides (DV200) ≥70%.

Samples were sequenced using the AmpliSeq for Illumina® Transcriptome 203 Human Gene Expression Panel<sup>23</sup> in a NextSeg 500/550 system. Raw data were 204 evaluated using FastQC<sup>24</sup>. STAR<sup>25</sup> was employed to align high-quality data 205 GRCh37/hg19 as a reference. Gene counts 206 usina obtained using featureCounts<sup>26</sup> were normalized using Voom transformation and guantile 207 normalization in limma.<sup>27</sup> Genes with low counts were filtered using EdgeR.<sup>28</sup> 208 209 Outliers and possible batch effects detected using principal component analysis (PCA) were corrected using limma linear models.<sup>27</sup> Finally, the transcriptomic 210 211 variation due to endometrial luteal phase timing effects was detected using a

10

transcriptomic endometrial dating (TED) model established by our group,<sup>19</sup> then
removed using limma as we previously described.<sup>12</sup> Additional details about the
TED model are presented in **Supplementary Material**.

## 215 Clinical classification of patients

216 Patients were initially classified based on their clinical history of implantation 217 failures. Implantation failure was considered for patients who presented a 218 negative beta chorionic gonadotropin ( $\beta$ -hCG) value ( $\leq 10$  IU/L) 14–16 days 219 following embryo transfer, or a biochemical miscarriage (defined by a positive serum  $\beta$ -hCG value, but absence of pregnancy within the first 10 weeks of 220 gestation).<sup>14</sup> Patients with at least three implantation failures were initially 221 222 classified as having an endometrium with a poor prognosis whereas patients 223 who achieved implantation success within the first three attempts, were initially 224 classified as having an endometrium with a good prognosis. Patients with 225 insufficient attempts were excluded from further analyses (n=62).

#### 226 Patient stratification based on Al algorithms

A training set (80% of samples) was employed to identify a biomarker signature for endometrial disruption in the mid-secretory phase, stratify patients and develop an AI-based prediction model that was externally validated in an independent testing set (20% of samples).

The training set was used for endometrial gene signature discovery, as previously described.<sup>19</sup> Briefly, genes were listed in decreasing order, based on an informativity score, using CorrelationAttributeEval<sup>29</sup> in Weka.<sup>30</sup> To study the predictive performance of different sets of ordered genes, five-fold crossvalidation processes with 100 iterations were performed independently with

11

support vector machine (SVM),<sup>31</sup> k-nearest neighbors (kNN)<sup>32</sup> and random 236 forest (RF) algorithms<sup>33</sup> using RWeka.<sup>34</sup> Among all the outputs, the signature 237 with the highest accuracy and most genes was selected and used to develop a 238 balanced probabilistic model (Supplementary Material). The probabilistic 239 model was internally evaluated through cross-validation (5-fold, 10 times) in 100 240 241 different balanced models and their performance was evaluated with the test 242 set. The range of poor prognosis probabilities obtained by running the AI model 243 in all samples was used to stratify the study cohort into the following good (c) 244 and poor (p) prognosis profiles: c1 (probability $\leq 0.2$ ), c2 (probability> 0.2 & 245 probability<0.5), p2 (probability≥0.5 & probability<0.8), or p1 (probability≥0.8).

### 246 Molecular characterization of the different transcriptomic profiles

The differentially expressed genes (DEGs) [False Discovery Rate (FDR)<0.05] between profiles were identified using limma. Next, the functional differences between the profiles were revealed with gene set enrichment analyses (GSEA) performed using ClusterProfiler<sup>35</sup>. Biological functions were obtained from Kyoto Encyclopedia of Genes and Genomes (KEGG; September 2021 version)<sup>36</sup> while experimental annotated terms were obtained from Gene Ontology (GO; December 2021 version).<sup>37</sup>

#### 254 Remeasuring the expression of selected potential biomarkers

The expression of six DEGs was evaluated in 20 samples (five samples per transcriptomic profile) with quantitative polymerase chain reaction (qPCR) using beta-actin (*ACTB*) as a housekeeping gene. RNA was reverse transcribed into cDNA using the PrimeScript Reagent Kit (Perfect Real Time, Takara, Japan) on a Thermocycler T3000 (Biometra, Ireland). The qPCR was carried out using

12

260Power-Up SYBR Green (Thermo Fisher Scientific, MA, USA) on a StepOnePlus261System (Applied Biosystems, CA, USA). The specific primer sequences262(Invitrogen, Thermo Fisher Scientific, MA, USA) are presented in **Supplemental**263**Table 1**. Relative gene expression was calculated using the ΔΔCt method<sup>38</sup> and264ACTB as a housekeeping gene.

265

#### 266 Statistical analysis

267 Rates for reproductive outcomes [i.e., pregnancy (PR), cumulative pregnancy (CPR), live birth (LBR), biochemical miscarriage (BMR) and clinical miscarriage 268 (CMR)] were calculated as described in the Supplementary Material. 269 270 Descriptive statistics were used to ensure homogeny of the patients' baseline 271 clinical characteristics. Continuous variables were presented as an overall mean ± standard deviation, whereas discrete variables were presented as 272 counts and percentages. Statistical differences between groups were compared 273 274 using the Wilcoxon rank-sum test for continuous variables and the Fisher's 275 exact test for discrete variables. All statistical analyses were conducted in R (version 4.0.5, 2021-03-31).<sup>39</sup> Graphical results were generated with ggplot2.<sup>40</sup> 276 277 In all cases p<0.05 was considered statistically significant.

278

279

## RESULTS

# 280 Transcriptomic data and clinical characterization of patients

281 After quality control and analysis of available clinical information (see 282 **Supplementary Material** for details), 131 samples and 14,674 genes qualified

13

283 for evaluation. Patients were clinically classified as having an endometrium 284 associated with a poor (n=32) or good (n=99) prognosis based on the number of previous implantation failures. Both groups were homogeneous in terms of 285 main clinical variables (e.g., number of patients, age, body mass index, infertility 286 type and duration, endometrial dating) (Supplemental Table 2), ensuring that 287 288 there were no potential biases in endometrial-factor transcriptomic differences. 289 As expected, the number of transfers and implantation failures were significantly 290 different between groups (p-value=2.20e-16) due to the clinical classification 291 criteria used for this study. However, pairwise comparison revealed there were 292 no significant differences between the good prognosis groups (c1 and c2). 293 Batch effects were corrected to ensure the transcriptomic differences were 294 related to endometrial disruption independent of endometrial timing (see 295 Supplementary Material).

#### 296 Four new prognostic stratification groups for endometrial function

Participants were stratified into four profiles using a 236-gene signature and a probabilistic model that predicts endometrial profiles with 77% accuracy, 67% sensitivity and 80% specificity (see **Supplementary Material** for more details). The four profiles were established as poor (p) or good (c) according to the probability of presenting an endometrium associated with a poor prognosis: p1 (n=24) and p2 (n=14), c2 (n=32) and c1 (n=61). Clinical variables were homogenous for all stratified profiles (**Table 1**).

As expected, the number of transfers and implantation failures were significantly different between the four profiles. Profiles associated with a poor prognosis

14

showed lower PR (29.17%) and LBR (50.00%) coupled with higher CMR 306 307 (42.86%) and BMR (42.68%) compared to the good prognosis profiles (Figure 308 **2A**). These differences were statistically significant (p-value≤0.05) for all outcomes except CMR (Figure 2A). Interestingly, the p1 profile was related to a 309 higher rate of biochemical miscarriages, the p2 profile was related to clinical 310 311 miscarriages and the c1 profile was associated with the best reproductive 312 outcomes. When groups were compared pairwise significant differences were 313 found between the p1 and c1 groups in terms of PR (p-value=0.0011), LBR (p-314 value=0.0478) and BMR (p-value=0.0018); between p2 and c1 groups in terms 315 of LBR (p-value=0.0147) and CMR (p-value=0.0478), and finally, between the 316 p1 and c2 groups in terms of PR (p-value=0.004) (Figure 2B). Considering all 317 embryo transfer attempts, the cumulative PR reached 38% for p1, 76% for p2, 81% for c2, and 93% for c1 (**Figure 2C**). 318

#### 319 Molecular characterization of the transcriptomically-defined profiles

With respect to c1, there were 47 DEGs identified in p2, 3 DEGs in p1 and 1 DEG in c2. Only one transcript, mitogen-activated protein kinase 8 interacting protein 1 pseudogene (*LOC644172* or *MAPK8IP1P2*), was shared between p1 and c1 profiles, as well as c2 and c1 profiles (**Table 2**).

The p2 and p1 profiles showed the highest number of functional dysregulations compared to c1 (54 and 38 dysregulations, respectively). The downregulated functions (30/54, 55.6%) in p2 were mainly related to immune response (n=10) or metabolism and energy production (n=12). The upregulated functions (24/54, 44.4%) in p2 were mainly related with nervous system and sensory perception

15

(n=6), gene expression and protein degradation (n=6). Compared to the c1 profile, the p1 profile had mainly upregulated functions (27/38, 71.1%), which were related to immune responses (n=9), nervous system and sensory perception (n=6). Notably, most of the downregulated functions (11/38, 28.9%) in p1 were related to cellular movement and ciliary processes (n=6) (**Table 2**).

Both poor-prognosis-related profiles had a noticeable dysregulation of immune responses compared to the c1 profiles. However, the p1 was characterized by nine upregulated functions while the p2 was characterized by ten downregulated functions. The p2 profile also presented 12 downregulated functions related to metabolism and energy production (**Table 2**).

There were 22 functional dysregulations between the control profiles, with the c2 presenting a dysregulated profile similar to p2. Specifically, the c2 profile presented a downregulation of nine functions related to immune responses and an upregulation of five functions related to the nervous system and sensory perception (**Table 2**).

# Remeasuring expression of potential biomarkers of endometrial disruption

The expression of six DEGs was validated by qPCR. Three of these DEGs were identified in the p1 vs. c1 comparison [DND microRNA-mediated repression inhibitor 1 (*DND1*), synaptotagmin 10 (*SYT10*) and mitogen-activated protein kinase 8 interacting protein 1 pseudogene (*LOC644172*)] or c2 vs. c1 comparison (*LOC644172*). The remaining three DEGs were selected for having the highest absolute fold change between p2 and c1 [CF transmembrane

16

conductance regulator (*CFTR*), V-set domain containing T cell activation
inhibitor 1 (*VTCN1*) and solute carrier family 17 member 8 (*SLC17A8*)]. Except
for *SLC17A8* (**Supplemental Figure 4**), all genes showed the same gene
expression trends in qPCR and RNA-Seq, reinforcing their role as potential
biomarkers of endometrial disruption.

# 357 COMMENT

#### 358 Principal findings

This study is the first to stratify endometrial function into four transcriptomic profiles, independent of endometrial timing. The four transcriptomic profiles corresponded with significantly different reproductive rates, showing a gradient of prognoses and highlighting the complex nature of endometrial disruption in the mid-secretory phase.

## 364 Results in the context of what is known

365 Disrupted endometrial function, independent of luteal phase endometrial timing, was associated with a heterogeneous transcriptomic behavior among IVF 366 patients undergoing HRT, as previously reported in patients undergoing natural 367 cycles.<sup>10</sup> Our binary prediction model (good vs. poor prognosis) was based on a 368 369 signature of 236 genes that characterized the transcriptomic behavior with 67% 370 sensitivity. Our model's predictive performance exceeds that of Koot's binary 371 model, which was based on a larger signature of 301 genes and reached a 372 58.3% sensitivity when used to compare control and RIF patients in natural cycles.<sup>10</sup> Although we improved the predictive performance, these results 373

17

374 showed that using a dichotomous model to identify the gene expression 375 patterns associated with good or poor prognosis did not achieve sufficient power. Our last study in patients undergoing HRT showed that stratifying 376 patients using a 404-gene panel instead of clinical criteria significantly 377 enhanced the transcriptomic and clinical differences between poor and good 378 prognosis profiles.<sup>12</sup> However, the probabilistic model was not tested in an 379 380 independent test set, impeding comparison of the model's performance. Thus, in this study, the whole transcriptome was used to stratify patients into four 381 profiles according to an AI-computed probability of endometrial disruption. 382 383 Notably, the resulting gradient of prognoses distinguished two profiles that were 384 related to different types of miscarriages.

385

#### 386 Clinical and research implications

387 This work characterized four new prognostic profiles that can be used to predict 388 reproductive outcomes in IVF patients with a history of implantation failures. 389 Specifically, the p1 transcriptomic profile was related to the worst prognosis, 390 characterized by the highest BMR and the lowest PR. On a molecular level, the 391 p1 was associated with an excessive immune response, suggesting that a poor feto-maternal tolerance could be driving miscarriages in the early stages of 392 pregnancy.<sup>41</sup> Moreover, the overall downregulation of ciliary processes in this 393 cohort of patients with RIF reinforces their role in uterine disorders.<sup>42</sup> 394 395 Alternatively, the p2 profile was related to the highest CMR and a lack of 396 immune and metabolic responses. These findings suggest that implantation is 397 facilitated by an initial immune tolerance but miscarriage occurs in subsequent pregnancy stages due to energetic deficiencies. This novel hypothesis about 398

18

the relevance of the endometrial factor in clinical miscarriages requires further
investigation. Finally, there were two good prognosis profiles characterized by
high PRs and LBRs. The c1 profile was related to the highest LBR and lowest
BMR.

403 Overall, this new taxonomy can help improve the precision of diagnosis and 404 treatment of infertile women. It lays the groundwork for a new generation of 405 tools for evaluating patients with suspected endometrial-factor infertility or 406 stratifying types of miscarriages. Additionally, the molecular and functional 407 differences between the reproductive prognosis profiles set the foundation for 408 the discovery of new biomarkers and/or tailored therapeutic targets for each 409 specific transcriptomic profile.

#### 410 Strengths and limitations

This study proposed a novel stratification based on four whole-transcriptomebased profiles with a gradient of reproductive prognosis for IVF patients undergoing HRT, improving the results from the binary classification obtained in our previous studies.<sup>12</sup> Additionally, this approach leverages AI-computed probabilities which are more objective and robust than traditional approaches to classify patients with endometrial-factor infertility based on the number of implantation failures.

However, it is worth mentioning that due to the stratification into four groups and
the limited sample size by group, the AI model needs further optimization.
Further studies with larger patient cohorts are required to boost the statistical

19

421 power of the model for population inference, assess inter-cycle reproducibility,
422 and conduct rigorous prospective clinical trials prior to clinical implementation.<sup>43</sup>

423

424

#### 425 **Conclusions**

426 Regardless of endometrial timing, the heterogeneous endometrial function can 427 be leveraged to stratify IVF patients undergoing HRT. This study uncovers four 428 distinct prognostic groups reflecting disrupted molecular profiles related with the 429 highest BMR and CMR (p1 and p2, respectively) or less disrupted profiles 430 associated with the highest LBR (c1) and the highest PR (c2). These molecular 431 findings were linked to functional differences, highlighting overactive immune responses in p1 and decreased metabolism in p2, and revealing potential 432 mechanisms of actions underlying the biochemical and clinical miscarriages in 433 434 this cohort. Taken together, our results support that good and poor endometrial 435 prognoses have evident molecular and clinical differences. These findings 436 advance the research in personalized diagnostic and therapeutic strategies in 437 reproductive medicine, particularly for patients with endometrial-factor infertility.

438

#### 439 Acknowledgements

The authors thank the patients who participated in the study and the clinical staff who contributed to their recruitment, especially Elena Labarta, Juan Antonio García Velasco, Juan Giles, Ernesto Bosch, Agustín Ballesteros, Gema Castillón, Marcos Ferrando, Graciela Kohls, Francesca Gelosi, Laura Caracena,

20

Marga Esbert, Isabel Llorens, Cristina Gaya, Mónica Toribio, and Fernando
Quintana. We would like to thank Ester Castillo and Lourdes Fernandez from
Illumina® Spain, for their technical support for sequencing. Finally, we
acknowledge Raquel Amigo and Cristina Cardona from the Biobank and
Genomics Unit of the IIS La Fe, respectively, for assisting biopsy storing and
processing.

450

## 451 **REFERENCES**

- Strowitzki T, Germeyer A, Popovici R, Von Wolff M. The human
   endometrium as a fertility-determining factor. *Human Reproduction Update*.
   2006;12(5):617-630. doi:10.1093/humupd/dml033
- 455 2. Harper MJK. 10 The implantation window. *Baillière's Clinical Obstetrics and Gynaecology*. 1992;6(2):351-371. doi:10.1016/S0950-3552(05)80092-6
- Murphy CR. Uterine receptivity and the plasma membrane transformation.
   *Cell Res.* 2004;14(4):259-267. doi:10.1038/sj.cr.7290227
- 459 4. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. *American*460 *Journal of Obstetrics and Gynecology*. 1975;122(2):262-263.
  461 doi:10.1016/S0002-9378(16)33500-1

462 5. Wilcox AJ, Baird DD, Weinberg CR. Time of Implantation of the Conceptus
463 and Loss of Pregnancy. *New England Journal of Medicine*.
464 1999;340(23):1796-1799. doi:10.1056/nejm199906103402304

- 465
  6. Diaz-Gimeno P, Sebastian-Leon P, Sanchez-Reyes JM, et al. Identifying
  466 and optimizing human endometrial gene expression signatures for
  467 endometrial dating. *Human Reproduction*. 2022;37(2):284-296.
  468 doi:10.1093/humrep/deab262
- 469 7. Díaz-Gimeno P, Ruiz-Alonso M, Sebastian-Leon P, et al. Window of
  470 implantation transcriptomic stratification reveals different endometrial
  471 subsignatures associated with live birth and biochemical pregnancy. *Fertility*472 and Sterility. 2017;108(4):703-710. doi:10.1016/j.fertnstert.2017.07.007
- 473 8. Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, et al. A genomic
  474 diagnostic tool for human endometrial receptivity based on the
  475 transcriptomic signature. *Fertility and Sterility*. 2011;95(1).
- 476 doi:10.1016/j.fertnstert.2010.04.063

47 47 47 48	<ol> <li>Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, et al. The accuracy and reproducibility of the endometrial receptivity array is superior to his a diagnostic method for endometrial receptivity. <i>Fertil Steril</i>. 2013;9 517. doi:10.1016/j.fertnstert.2012.09.046</li> </ol>	
48 48 48	<ol> <li>Koot YEM, Van Hooff SR, Boomsma CM, et al. An endometrial ger expression signature accurately predicts recurrent implantation fail IVF. Sci Rep. 2016;6(1):19411. doi:10.1038/srep19411</li> </ol>	
48 48 48 48	<ol> <li>Sebastian-Leon P, Garrido N, Remohí J, Pellicer A, Diaz-Gimeno F Asynchronous and pathological windows of implantation: Two caus recurrent implantation failure. <i>Human Reproduction</i>. 2018;33(4):62 doi:10.1093/humrep/dey023</li> </ol>	ses of
48 48 49 49 49	<ol> <li>Diaz-Gimeno P, Sebastian-Leon P, Spath K, et al. Predicting risk o endometrial failure: a biomarker signature that identifies a novel dis independent of endometrial timing in patients undergoing hormona replacement cycles. <i>Fertility and Sterility</i>. Published online March 2024:S0015028224001900. doi:10.1016/j.fertnstert.2024.03.015</li> </ol>	sruption
49 49 49 49	<ol> <li>Duc-Goiran P, Mignot TM, Bourgeois C, Ferré F. Embryo–materna interactions at the implantation site: a delicate equilibrium. <i>Europea</i> of Obstetrics &amp; Gynecology and Reproductive Biology. 1999;83(1): doi:10.1016/S0301-2115(98)00310-8</li> </ol>	an Journal
49 49 49 50	<ol> <li>Pirtea P, Cedars MI, Devine K, et al. Recurrent implantation failure a statistical mirage?: Consensus statement from the July 1, 2022 L Workshop on recurrent implantation failure. <i>Fertility and Sterility</i>. 2023;120(1):45-59. doi:10.1016/J.FERTNSTERT.2023.02.014</li> </ol>	
50 50 50 50	<ol> <li>Cimadomo D, Craciunas L, Vermeulen N, Vomstein K, Toth B. Def diagnostic and therapeutic options in recurrent implantation failure: international survey of clinicians and embryologists. <i>Human Repro-</i> 2021;36(2):305-317. doi:10.1093/humrep/deaa317</li> </ol>	an
50 50 50 50	<ol> <li>Devesa-Peiro A, Sebastian-Leon P, Pellicer A, Diaz-Gimeno P. Gu for biomarker discovery in endometrium: correcting for menstrual c reveals new genes associated with uterine disorders. <i>Molecular hu</i> <i>reproduction</i>. 2021;27(4):gaab011. doi:10.1093/MOLEHR/GAAB01</li> </ol>	ycle bias <i>iman</i>
50 51 51 51	<ol> <li>Diaz-Gimeno P, Horcajadas JA, Martinez-Conejero JA, et al. A ger diagnostic tool for human endometrial receptivity based on the transcriptomic signature. <i>Fertility and Sterility</i>. 2011;95(1):50-60. doi:10.1016/j.fertnstert.2010.04.063</li> </ol>	omic
51 51 51 51 51	<ol> <li>Diaz-Gimeno P, Ruiz-Alonso M, Sebastian-Leon P, Pellicer A, Valk Simon C. Window of implantation transcriptomic stratification revea different endometrial subsignatures associated with live birth and biochemical pregnancy. <i>Fertility and Sterility</i>. 2017;108(4):703-710 doi:10.1016/j.fertnstert.2017.07.007</li> </ol>	als

518	19. Diaz-Gimeno P, Sebastian-Leon P, Sanchez-Reyes JM, et al. Identifying
519	and optimizing human endometrial gene expression signatures for
520	endometrial dating. <i>Human Reproduction</i> . 2022;37(2):284-296.
521	doi:10.1093/humrep/deab262
522	<ol> <li>Guttmacher AE, Collins FS. Genomic Medicine — A Primer. Guttmacher</li></ol>
523	AE, Collins FS, eds. N Engl J Med. 2002;347(19):1512-1520.
524	doi:10.1056/NEJMra012240
525 526	21. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. <i>N Engl J Med.</i> 2012;366(6):489-491. doi:10.1056/NEJMp1114866
527 528	22. Bell J. Stratified medicines: towards better treatment for disease. <i>The Lancet</i> . 2014;383:S3-S5. doi:10.1016/S0140-6736(14)60115-X
529	23. Illumina. AmpliSeq for Illumina Transcriptome Human Gene Expression
530	Panel. 2021. Accessed December 17, 2021.
531	https://www.illumina.com/products/by-type/sequencing-kits/library-prep-
532	kits/ampliseq-transcriptome-gene-expression-panel.html
533 534 535	24. Andrews S, Krueger F, Segonds-Pichon A, Biggins L, Krueger C, Wingett S. FastQC: a quality control tool for high throughput sequence data. Published online 2010. http://www.bioinformatics.babraham.ac.uk/projects/fastqc
536 537	25. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> . 2013;29(1):15-21. doi:10.1093/bioinformatics/bts635
538	<ol> <li>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose</li></ol>
539	program for assigning sequence reads to genomic features. <i>Bioinformatics</i> .
540	2014;30(7):923-930. doi:10.1093/bioinformatics/btt656
541	<ol> <li>Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression</li></ol>
542	analyses for RNA-sequencing and microarray studies. <i>Nucleic Acids</i>
543	<i>Research.</i> 2015;43(7):e47. doi:10.1093/nar/gkv007
544 545 546 547	28. Chen Y, Lun ATL, Smyth GK. From reads to genes to pathways: Differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. <i>F1000Research</i> . 2016;5. doi:10.12688/F1000RESEARCH.8987.2
548 549 550	29. Witten IH, Frank E, Hall MA, Pal CJ. <i>Data Mining: Practical Machine Learning Tools and Techniques</i> . Morgan Kaufmann; 2016. doi:https://doi.org/10.1016/C2015-0-02071-8
551	<ol> <li>Frank E, Hall M, Holmes G, et al. Weka-A Machine Learning Workbench for</li></ol>
552	Data Mining. In: <i>Data Mining and Knowledge Discovery Handbook</i> . Springer
553	US; 2009:1269-1277. doi:10.1007/978-0-387-09823-4_66
554	<ol> <li>Noble WS. What is a support vector machine? Nature Biotechnology.</li></ol>
555	2006;24(12):1565-1567. doi:10.1038/nbt1206-1565

23

- 32. Zhang Z. Introduction to machine learning: K-nearest neighbors. Annals of
   *Translational Medicine*. 2016;4(11). doi:10.21037/atm.2016.03.37
- 33. Breiman L. Random forests. *Machine Learning*. 2001;45(1):5-32.
   doi:10.1023/A:1010933404324
- 34. Hornik K, Buchta C, Zeileis A. Open-source machine learning: R meets
   Weka. *Comput Stat.* 2009;24(2):225-232. doi:10.1007/s00180-008-0119-7
- 35. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: An R package for
   comparing biological themes among gene clusters. *OMICS: A Journal of Integrative Biology*. 2012;16(5):284-287. doi:10.1089/omi.2011.0118
- 36. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes.
   *Nucleic Acids Research*. 2000;28(1):27-30. doi:10.1093/nar/28.1.27
- 37. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: Tool for the
  unification of biology. *Nature Genetics*. 2000;25(1):25-29.
- 569 doi:10.1038/75556
- 570 38. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using 571 Real-Time Quantitative PCR and the  $2-\Delta\Delta$ CT Method. *Methods*.
- 572 2001;25(4):402-408. doi:10.1006/meth.2001.1262
- 39. R Core Team. *R: A Language and Environment for Statistical Computing*. R
   Foundation for Statistical Computing; 2021. https://www.R-project.org/
- 40. Wickham H. *Ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag
   New York; 2016. https://ggplot2.tidyverse.org
- 41. Sargent IL, Wilkins T, Redman CWG. Maternal immune responses to the
  fetus in early pregnancy and recurrent miscarriage. *The Lancet*.
  1988;2(8620):1099-1104. doi:10.1016/S0140-6736(88)90522-3
- 42. Devesa-Peiro A, Sebastian-Leon P, Garcia-Garcia F, et al. Uterine disorders
  affecting female fertility: what are the molecular functions altered in
  endometrium? *Fertility and Sterility*. 2020;113(6):1261-1274.
- 583 doi:10.1016/j.fertnstert.2020.01.025
- 43. Diaz-Gimeno P, Sebastian-Leon P, Pellicer A. Reply of the Authors: Altered
  endometrial receptivity: walking across the long path of precision medicine. *Fertility and Sterility*. 2024;122(3):551. doi:10.1016/j.fertnstert.2024.06.010
- 587

589 590	TABLES
591	
592	Table 1. Baseline characteristics and reproductive history of the stratified
593	groups. Endometrial profiles (c1, c2, p2, and p1) are compared according to
594	the main clinical variables related to reproductive outcomes. Using the
595	transcriptomic endometrial dating (TED) model, endometria in early and late
596	secretory (ESE;LSE) classes were grouped as displaced (Ds) while early and
597	late mid-secretory (EMSE;LMSE) classes were grouped as on time (Ot). BMI,
598	body mass index; N/A, not available; No., number of.; P, primary; S, secondary.
599	***p-value < 0.001; <sup>a</sup> p-value < 0.05 in p1 vs. c1; <sup>b</sup> p-value < 0.05 in p1 vs. c2; <sup>c</sup> p-
600	value < 0.05 in p2 vs. c1; $^{d}$ p-value < 0.05 in p2 vs. c2; $^{e}$ p-value < 0.05 in p2 vs.
601	p1.

25

	<b>c1</b>	c2	р2	р1	p-value		
No. patients	61	32	14	24	N/A		
Age (years)	40.77 ± 4.41	39.84 ± 4.97	40.14 ± 4.44	42.5 ± 3.56	0.1686		
BMI (kg/m²)	23.62 ± 3.97	22.53 ± 3.47	22.53 ± 3.34	22.22 ± 3.68	0.3324		
Infertility type	P = 48 (82.8%) S = 10 (17.2%) N/A = 3	P = 23 (79.3%) S = 6 (20.7%) N/A = 3	P = 12 (92.3%) S = 1 (7.7%) N/A = 1	P = 18 (85.7%) S = 3 (14.3%) N/A = 3	0.8501		
Infertility duration (years)	2.95 ± 2.86	3.31 ± 3.10	3.58 ± 1.87	2.8 ± 1.7	0.7943		
Endometrial dating (TED)	Ds = 41 (67.2%) Ot = 20 (32.8%)	Ds = 18 (56.3%) Ot = 14 (43.7%)	Ds = 7 (50.0%) Ot = 7 (50.0%)	Ds = 17 (70.8%) Ot = 7 (29.2%)	0.4354		
No. embryo transfers	1.75 ± 0.85	1.78 ± 0.91	2.71 ± 1.44	4.21 ± 1.32	5E-17 *** a, b, c, d, e		
No. implan- tation fail- ures	0.75 ± 0.85	0.81 ± 1.00	2.00 ± 1.75	3.79 ± 1.14	4E-22 *** a, b, c, d, e		

603

Table 2. Molecular regulation and functional differences between endometrial profiles. The table shows the number of differentially expressed genes (DEGs) and the corresponding number of significantly up- or downregulated biological functions [False Discovery Rate (FDR) < 0.05], identified through a gene set enrichment analysis (GSEA), for each comparison. The number of biological functions in each functional groups is indicated between brackets.

	p1 vs. c1 p1 vs. c2		p1 vs. p2		p2 vs. c1		p2 vs. c2		c2 vs. c1			
DEGs	3		0		0		47		0		1	
Functional Groups	UP	DOWN	UP	DOWN	UP	DOWN	UP	DOWN	UP	DOWN	UP	DOWN
Immune response (n=26)	9	0	9	0	7	1	3	10	6	2	0	9
Nervous system and sensory perception (n=6)	6	0	1	1	1	1	6	0	2	0	5	0
Signal transduction (n=7)	3	2	2	2	0	0	2	0	0	0	1	0
Metabolism and energy production (n=26)	3	2	3	3	0	2	1	12	3	6	0	0
Cellular movement and ciliary processes (n=8)	2	6	0	0	0	0	0	3	0	2	0	1
Cellular adhesion and membranes (n=11)	1	0	0	0	3	2	3	3	3	2	3	0
Gene expression and protein degradation (n=13)	1	0	1	0	2	4	6	2	6	2	0	3
Proliferation and differentiation (n=2)	1	1	1	0	0	0	0	0	0	0	0	0
Longevity and senescence (n=2)	1	0	0	0	0	0	1	0	0	0	0	0
Angiogenesis and coagulation (n=3)	0	0	0	0	0	2	2	0	1	0	0	0
	27	11	17	6	13	12	24	30	21	14	9	13
DYSREGULATED FUNCTIONS		38		23		25		54		35		22

27

615

#### **FIGURE CAPTIONS**

616 Figure 1. Study design. In vitro fertilization (IVF) patients undergoing hormone replacement therapy (HRT) were classified as having good or bad endometrial 617 618 prognosis profiles based on their reproductive histories. Endometrial biopsies were processed for whole-transcriptome RNA-Sequencing. Following RNA-619 620 Sequencing data normalization, the effect of endometrial luteal-phase timing 621 was corrected. Subsequently, an artificial intelligence model was developed to 622 stratify the population into four groups according to their probability of having a 623 poor prognosis. Transcriptomic evaluation and functional characterization were 624 followed by an analysis of clinical reproductive outcomes profiles are clinically 625 relevant.

Figure 2. Clinical evaluation of transcriptomic profiles. (A) Bar plot showing the significant differences obtained through pairwise comparisons of different profiles. PR, Pregnancy rate; LBR, Live birth rate; CMR, Clinical miscarriage rate; BMR, Biochemical miscarriage rate. (B) Bar plot showing the cumulative pregnancy rate from multiple embryo transfers. \*p-value < 0.05; \*\*p-value < 0.01; \*\*\*p-value < 0.001.

632

#### 633 SUPPLEMENTARY MATERIAL

634 Supplemental Table 1. Specific primers employed for qPCR
 635 remeasurementof endometrial disruption biomarkers.

636 *CFTR*, CF transmembrane conductance regulator; *DND1*, MicroRNA-mediated 637 repression inhibitor 1; FW, forward; *MAPK8IP1P2, mitogen-activated protein* 

28

*kinase 8 interacting protein 1 pseudogene 2*, also known as *LOC644172*;
qPCR, quantitative polymerase chain reaction; RV, reverse; *SLC17A8*, solute
carrier family 17 member 8; *SYT10*, synaptotagmin; *VTCN1*, V-set domain
containing T cell activation inhibitor 1.

Supplemental Table 2. Homogeneity of the baseline characteristics in
 poor and good endometrial prognosis groups.

With the transcriptomic endometrial dating (TED) model, early and late secretory (ESE;LSE) classes were grouped as displaced while early and late mid-secretory (EMSE;LMSE) classes were grouped as on time. BMI, body mass index; N/A, not available; No., number of. \*\*\*p-value < 0.001.

**Supplemental Table 3. Homogeneity of the baseline characteristics in training and test sets.** Baseline characteristics of training and test sets are shown. With the transcriptomic endometrial dating (TED) model, early and late secretory (ESE;LSE) classes were grouped as displaced while early and late mid-secretory (EMSE;LMSE) classes were grouped as on time. BMI, body mass index; N/A, not available; No., number of. \*p-value < 0.05; \*\*\*p-value < 0.001.

655 Supplemental Table 4. Comparison of Al model performance metrics.

The table shows the performance metrics (accuracy, sensitivity, and specificity) for individual machine learning models (SVM, RF, kNN) and their combinations (SVM+kNN, SVM+RF, kNN+RF). kNN, k-Nearest neighbors; RF, Random forest; SVM, Support vector machine.

660 **Supplemental Figure 1. Principal component analysis (PCA) results. (A)** 661 PCA plot identifying two outliers (V10 and Bi16), which were excluded from


29


subsequent analyses. (B) PCA plots depicting the batch effect from the 662 663 sequencing run before and after correction. (C) PCA plots depicting the endometrial timing effect obtained using the 73-gene TED signature before and 664 after correction. EMSE, early mid-secretory; ESE, early secretory; LMSE, late 665 LSE. late secretory; PC, 666 mid-secretory; principal component; TED, 667 transcriptomic endometrial dating.


Supplemental Figure 2. Exploratory analysis of RNA quality parameters.
Principal component analysis (PCA) plots for the (A) 260/230 ratio, (B) 260/280
ratio, (C) RNA fragments with more than 200 nucleotides (DV200), and (D) RNA
integrity number (RIN). No batch effects were observed for these parameters.


572 Supplemental Figure 3. Selection of the poor endometrial prognosis gene 573 signature. Graphs highlighting the maximum number of endometrial genes the 574 (A) Support vector machine (SVM), (B) k-Nearest neighbors (kNN) and (C) 575 Random Forest (RF) models can process with the highest accuracy. The 576 orange dotted line represents the percentage obtained with an unbalanced 577 proportion of good and poor prognosis classes.

Supplemental Figure 4. qPCR validation of endometrial disruption
biomarkers. Comparison of gene expression fold change obtained with RNASequencing (RNA-Seq) and quantitative polymerase chain reaction (qPCR)
assays. Six differentially expressed genes (DEGS) were selected from (A) p1
vs. c1, (B) p2 vs. c1, (C) c2 vs. c1 comparisons.









No. embryo transfers

B)

A)